GM-CSF to Decrease ICU Acquired Infections

PHASE3CompletedINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

September 14, 2015

Primary Completion Date

June 1, 2018

Study Completion Date

June 1, 2018

Conditions
Septic ShockSevere Sepsis
Interventions
DRUG

Sargramostim: Leukine (Genzyme USA)

Leukine: 125 µg/m² daily, subcutaneously, for 5 days.

DRUG

Placebo

placebo subcutaneously, for 5 days

Trial Locations (18)

13005

APHM Hopital de la Timone, Marseille

CHU la Conception, Marseille

13915

APHM Hopital Nord, Marseille

30029

CHU de Nîmes, Nîmes

34295

CHU Montpellier, Montpellier

Hopital Saint Eloi, Montpellier

38043

CHU de Grenoble- Hopital Michallon, Grenoble

CHU de Grenoble-Hopital Michallon, Grenoble

42055

CHU de Saint-Etienne, Saint-Etienne

CHU Hopital Nord, Saint-Etienne

44093

CHU de Nantes, Nantes

PTMC CHU de Nantes, Nantes

63003

CHU Estaing 1 place Lucie et Raymond Aubrac, Clermont-Ferrand

CHU Gabriel MONTPIED, Clermont-Ferrand

69003

Hopital Edouard Herriot, Lyon

69317

Hopital de la Croix Rousse, Lyon

69495

Centre hospitalier Lyon Sud, Pierre-Bénite

80054

CHU Amiens Hopital SUD, Amiens

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT02361528 - GM-CSF to Decrease ICU Acquired Infections | Biotech Hunter | Biotech Hunter